103 related articles for article (PubMed ID: 3487268)
21. Chemotactic properties of partially purified human epidermal cell-derived thymocyte-activating factor (ETAF) for polymorphonuclear and mononuclear cells.
Luger TA; Charon JA; Colot M; Micksche M; Oppenheim JJ
J Immunol; 1983 Aug; 131(2):816-20. PubMed ID: 6602848
[TBL] [Abstract][Full Text] [Related]
22. The role of Ia molecules in the activation of T lymphocytes. IV. The basis of the thymocyte IL 1 response and its possible role in the generation of the T cell repertoire.
Rock KL; Benacerraf B
J Immunol; 1984 Apr; 132(4):1654-62. PubMed ID: 6421925
[TBL] [Abstract][Full Text] [Related]
23. Presence of epidermal-derived thymocyte activating factor/interleukin 1 in normal human stratum corneum.
Gahring LC; Buckley A; Daynes RA
J Clin Invest; 1985 Oct; 76(4):1585-91. PubMed ID: 2997285
[TBL] [Abstract][Full Text] [Related]
24. Epidermal cell thymocyte-activating factor.
Sauder DN
Adv Dermatol; 1986; 1():237-46. PubMed ID: 3079245
[TBL] [Abstract][Full Text] [Related]
25. 1,25-Dihydroxyvitamin D3 (calcitriol) suppresses IL-2 induced murine thymocyte proliferation.
Haq AU
Thymus; 1986; 8(5):295-306. PubMed ID: 3492067
[TBL] [Abstract][Full Text] [Related]
26. Neutrophil product with lymphocyte activating factor activity.
Harris PJ
Clin Exp Immunol; 1982 Dec; 50(3):474-8. PubMed ID: 6984667
[TBL] [Abstract][Full Text] [Related]
27. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1.
Zhang J; Cado D; Chen A; Kabra NH; Winoto A
Nature; 1998 Mar; 392(6673):296-300. PubMed ID: 9521326
[TBL] [Abstract][Full Text] [Related]
28. In vitro analysis of allogeneic lymphocyte interaction. VIII. Characterization of helper components of allogeneic effect factor (AEF) that activate Lyb5+ and Lyb5- B cells to respond to thymus-dependent and thymus-independent antigens.
Delovitch TL; Kaufman K; Gorczynski RD; Sinclair GD
J Immunol; 1983 Nov; 131(5):2246-53. PubMed ID: 6605380
[TBL] [Abstract][Full Text] [Related]
29. Hydrocortisone reduces both constitutive and UV-elicited release of epidermal thymocyte activating factor (ETAF) by cultured keratinocytes.
Kupper TS; McGuire J
J Invest Dermatol; 1986 Nov; 87(5):570-3. PubMed ID: 3534102
[TBL] [Abstract][Full Text] [Related]
30. Induction of interleukin 2 responsiveness in thymocytes by synergistic action of interleukin 1 and interleukin 2.
Männel DN; Mizel SB; Diamantstein T; Falk W
J Immunol; 1985 May; 134(5):3108-10. PubMed ID: 3920312
[TBL] [Abstract][Full Text] [Related]
31. Identification and induction of human keratinocyte-derived IL-12.
Müller G; Saloga J; Germann T; Bellinghausen I; Mohamadzadeh M; Knop J; Enk AH
J Clin Invest; 1994 Nov; 94(5):1799-805. PubMed ID: 7962524
[TBL] [Abstract][Full Text] [Related]
32. Autocrine growth stimulation of human keratinocytes by epidermal cell-derived thymocyte-activating factor: implications for skin aging.
Sauder DN; Stanulis-Praeger BM; Gilchrest BA
Arch Dermatol Res; 1988; 280(2):71-6. PubMed ID: 3260767
[TBL] [Abstract][Full Text] [Related]
33. Human T-cell growth factor (TCGF).
Sarin PS; Gallo RC
Crit Rev Immunol; 1984; 4(4):279-305. PubMed ID: 6232114
[No Abstract] [Full Text] [Related]
34. Lymphokines: their role in lymphocyte responses. Properties of interleukin 1.
Oppenheim JJ; Stadler BM; Siraganian RP; Mage M; Mathieson B
Fed Proc; 1982 Feb; 41(2):257-62. PubMed ID: 6800841
[TBL] [Abstract][Full Text] [Related]
35. Analysis of clonal responses to B-cell-tropic interleukins.
Wetzel GD
Lymphokine Res; 1983; 2(4):133-7. PubMed ID: 6332248
[No Abstract] [Full Text] [Related]
36. Possible relevance to dermatology of epidermal cell thymocyte-activating factor (ETAF).
Luger TA
Am J Dermatopathol; 1983 Feb; 5(1):97-102. PubMed ID: 6602566
[No Abstract] [Full Text] [Related]
37. A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells.
Friend SL; Hosier S; Nelson A; Foxworthe D; Williams DE; Farr A
Exp Hematol; 1994 Mar; 22(3):321-8. PubMed ID: 8112430
[TBL] [Abstract][Full Text] [Related]
38. IL-2-mediated cell cycle progression and inhibition of apoptosis does not require NF-kappa B or activating protein-1 activation in primary human T cells.
Iacobelli M; Rohwer F; Shanahan P; Quiroz JA; McGuire KL
J Immunol; 1999 Mar; 162(6):3308-15. PubMed ID: 10092783
[TBL] [Abstract][Full Text] [Related]
39. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects.
Fontana A; Hengartner H; de Tribolet N; Weber E
J Immunol; 1984 Apr; 132(4):1837-44. PubMed ID: 6607949
[TBL] [Abstract][Full Text] [Related]
40. Lymphocyte activation. V. Quantitation of the proliferative responses to mitogens using defined T and B cell populations.
Janossy G; Greaves MF; Doenhoff MJ; Snajdr J
Clin Exp Immunol; 1973 Aug; 14(4):581-96. PubMed ID: 4583779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
